IQV

IQVIA Holdings
D

IQV

Arincen71/100B

IQVIA Holdings financials

Yes. IQVIA Holdings earned 1.39B USD of net income over the last twelve months, 8.1% of its revenue. It made a profit in 16 of its 16 fiscal years since 2010.

Revenue (TTM)
17.31B USD
Net income (TTM)
1.39B USD
Free cash flow (TTM)
2.08B USD
Cash and short-term investments
2.42B USD
Total debt
16.31B USD
Shareholders' equity
6.66B USD

Cash, debt and equity as of 30 Sept 2026.

IQVIA Holdings earnings

Next earnings · Q4 FY2026
EPS estimate
3.60 USD
Revenue estimate
4.53B USD
Last quarter · Q3 FY2026
EPS3.34Beat +2.5%Revenue4.43BBeat +1.4%

Revenue

ReportedEstimate

EPS

ReportedEstimate
PeriodReport dateEPS estimateReported EPSSurpriseEPS growthRevenue estimateReported revenueSurpriseRevenue growth
Q3 FY20273.60——+7.64%4.66B——+5.30%
Q2 FY20273.44——+9.10%4.61B——+5.46%
Q1 FY20273.16——+9.11%4.45B——+7.15%
Q4 FY20263.60——+5.26%4.53B——+3.72%
Q3 FY20263.263.34+2.45%+11.33%4.37B4.43B+1.44%+8.00%
Q2 FY20263.033.15+3.96%+12.10%4.30B4.37B+1.53%+8.74%
Q1 FY20262.822.90+2.84%+7.41%4.10B4.15B+1.24%+8.41%
Q4 FY20253.403.42+0.59%+9.62%4.24B4.36B+2.93%+10.26%
Q3 FY20252.983.00+0.67%+5.63%4.08B4.10B+0.50%+5.24%
Q2 FY20252.772.81+1.44%+6.44%3.97B4.02B+1.19%+5.32%

IQVIA Holdings growth and profitability

Full income statement
Revenue (TTM)
17.31B USD
Net income (TTM)
1.39B USD
Gross margin
26.46%
Operating margin
12.82%
Net margin
8.05%

Revenue / Net income

Revenue Net income Net margin
PeriodRevenueGrowthNet incomeGrowthGross marginOperating marginNet marginEBITDAGrowth
FY202516.31B+5.87%1.36B-0.95%33.29%13.38%8.34%2.94B-14.91%
FY202415.41B+2.81%1.37B+1.10%34.89%14.29%8.91%3.45B+6.05%
FY202314.98B+3.98%1.36B+24.47%34.96%13.19%9.06%3.26B+11.93%
FY202214.41B+3.86%1.09B+12.94%34.89%12.48%7.57%2.91B+5.13%
FY202113.87B+22.14%966.00M+246.24%33.45%10.04%6.96%2.77B+33.29%

How IQVIA Holdings makes its money

Research And Development Solutions8.90B 54.5%
Technology And Analytics Solutions6.63B 40.6%
Contract Sales And Medical Solutions788.00M 4.8%
Revenue16.31B 100.0%
Cost of revenue10.88B 66.7%
Gross profit5.43B 33.3%
Selling and administration1.99B 12.2%
Other operating expenses1.26B 7.7%
Operating income2.18B 13.4%
Tax252.00M 1.5%
Other expense570.00M 3.5%
Net income1.36B 8.3%

FY2025, in USD. Each band is as wide as its money; the percentage is its share of revenue.

IQVIA Holdings revenue breakdown

By product

FY2025
Research And Development Solutions: 54.5%Technology And Analytics Solutions: 40.6%Contract Sales And Medical Solutions: 4.8%54.5%Research And Development Solutions40.6%Technology And Analytics Solutions4.8%Contract Sales And Medical Solutions
SegmentRevenueShare of revenueChange on the year
Research And Development Solutions8.90B54.5%+4.3%
Technology And Analytics Solutions6.63B40.6%+7.6%
Contract Sales And Medical Solutions788.00M4.8%+9.7%

By region

FY2025
Americas: 47.5%EMEA: 31.8%Asia Pacific: 20.7%47.5%Americas31.8%EMEA20.7%Asia Pacific
RegionRevenueShare of revenueChange on the year
Americas7.75B47.5%+5.3%
EMEA5.19B31.8%+5.4%
Asia Pacific3.38B20.7%+8.0%

Operating and free cash flow

Full cash flow statement
Operating cash flow Free cash flow
Fiscal yearOperating cash flowFree cash flow
FY20252.65B2.05B
FY20242.72B2.11B
FY20232.15B1.50B
FY20222.26B1.59B
FY20212.94B2.30B
FY20201.96B1.34B
FY20191.42B835.00M
FY20181.25B795.00M
FY2017970.00M601.00M
FY2016860.00M696.00M

IQVIA Holdings financial health

Full balance sheet
Cash and short-term investments
2.42B USD
Total debt
16.31B USD
Net cash
-13.89B USD
Free cash flow (TTM)
2.08B USD
Current ratio
0.83
Debt to equity
2.45
Piotroski score
8 / 9
Altman Z-score
2.29

Cash, debt and free cash flow

Cash and short-term investments Total debt Free cash flow
Fiscal yearCash and short-term investmentsTotal debtFree cash flow
FY20252.14B16.17B2.05B
FY20241.84B14.16B2.11B
FY20231.50B13.90B1.50B
FY20221.31B13.01B1.59B
FY20211.48B12.44B2.30B

Assets, liabilities and equity

Total assets Total liabilities Shareholders' equity
Fiscal yearTotal assetsTotal liabilitiesShareholders' equity
FY202529.94B23.31B6.50B
FY202426.90B20.83B6.07B
FY202326.68B20.57B6.11B
FY202225.34B19.57B5.77B
FY202124.69B18.65B6.04B
FY202024.56B18.28B6.00B
FY201923.25B16.99B6.00B
FY201822.55B15.60B6.71B
FY201722.74B14.38B8.11B
FY201621.21B12.35B8.63B

IQVIA Holdings valuation

Price to earnings ratio (TTM)
31.85
Forward P/E (FY2026)
20.44
Price to sales (TTM)
2.52
Price to book
6.56
EV / EBITDA (TTM)
16.00

Capital structure

Market capitalization
43.67B USD
+
Total debt
16.31B USD
−
Cash and short-term investments
2.42B USD
=
Enterprise value
57.56B USD

Valuation over time

P/EForward P/EForward P/E · EstimateEstimate
Fiscal yearP/EForward P/EP/SP/BEV/EBITDA
FY2028 (est.)16.65————
FY2027 (est.)18.7116.65———
FY2026 (est.)20.4418.71———
Now (TTM)31.8518.912.526.5616.00
FY202528.5017.392.385.9618.02
FY202425.9616.532.315.8713.92
FY202331.3120.812.846.9616.91
FY202235.2020.102.676.6717.27
FY202155.8727.803.898.9423.52

IQVIA Holdings against its own history

Each figure in the latest fiscal year against the same figure from FY2021 to FY2025: the range, its median (the line) and the latest (the dot, green on the good side of the median). The P/E is today's against its daily readings of five years.

Its peers: Waters, Agilent Technologies, Natera, IDEXX Laboratories, Mettler-Toledo International, and Illumina, the US Medical - Diagnostics & Research companies closest to it in size, each in its own latest fiscal year: their median (the line) and its rank among them, first being the best.

  • P/E (today)Below its median31.8
    18.570.6
  • Gross marginLowest in 5 years33.3%
    33.3%35.0%
    Against its peers: 7 of 7Peers' median 60.6%
  • Operating marginAbove its median13.4%
    10.0%14.3%
    Against its peers: 6 of 7Peers' median 24.5%
  • Net marginAt its median8.3%
    7.0%9.1%
    Against its peers: 6 of 7Peers' median 19.9%
  • Return on equityAt its median20.9%
    16.0%22.6%
    Against its peers: 4 of 6Peers' median 25.1%
  • Free cash flow marginAt its median12.6%
    10.0%16.6%
    Against its peers: 6 of 7Peers' median 19.1%
  • Revenue growthAbove its median5.9%
    2.8%22.1%
    Against its peers: 5 of 7Peers' median 6.9%
  • EPS growthBelow its median4.7%
    2.7%246.2%
    Against its peers: 2 of 5Peers' median 3.5%
  • Debt to EBITDAHighest in 5 years5.51×
    4.10×5.51×
    Against its peers: 6 of 6Peers' median 1.75×
  • Current ratioLowest in 5 years0.75
    0.750.91
    Against its peers: 7 of 7Peers' median 1.85

Peers: US companies of the same industry (of its sector when the industry has too few) from a tenth to ten times its market value, the six closest in size. Updated weekly.

IQVIA Holdings ownership

Institutions
94.02%
Institutional holders
1,123 (+17)
Free float
94.93%

Who owns the shares

Institutions 94.0% Others 6.0%
As of 30 Jun 2026

Shares free to trade

Free float 156.45M shares ·94.9% Closely held 8.35M shares ·5.1%

Closely held shares belong to insiders, founders and owners of more than 5%, and seldom change hands. The free float is the rest: the shares anyone can buy and sell.

Insider trading

QuarterPurchasesSalesShares acquiredShares disposed of
Q3 202609162.27K336.09K
Q2 20260013.37K0.00
Q1 202600315.99K50.58K
Q4 202508138.27K275.18K

Shares outstanding

Basic shares Diluted shares Change in diluted shares
Fiscal yearBasic sharesDiluted sharesChange in diluted shares
FY2025171.90M173.50M-5.40%
FY2024181.30M183.40M-1.56%
FY2023183.80M186.30M-2.26%
FY2022187.60M190.60M-2.26%
FY2021191.40M195.00M0.00%

Common questions about IQVIA Holdings's financials

Source: Financial Modeling PrepVerified against SEC filings